Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Finished Goods (2023 - 2025)

Historic Finished Goods for Cytosorbents (CTSO) over the last 3 years, with Q3 2025 value amounting to $2.3 million.

  • Cytosorbents' Finished Goods changed N/A to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year change of. This contributed to the annual value of $1.7 million for FY2024, which is 1032.58% down from last year.
  • According to the latest figures from Q3 2025, Cytosorbents' Finished Goods is $2.3 million.
  • Over the past 5 years, Cytosorbents' Finished Goods peaked at $2.4 million during Q2 2025, and registered a low of $1.7 million during Q4 2024.
  • Moreover, its 3-year median value for Finished Goods was $1.9 million (2023), whereas its average is $2.0 million.
  • The largest annual percentage gain for Cytosorbents' Finished Goods in the last 5 years was 1032.58% (2024), contrasted with its biggest fall of 1032.58% (2024).
  • Over the past 3 years, Cytosorbents' Finished Goods (Quarter) stood at $1.9 million in 2023, then dropped by 10.33% to $1.7 million in 2024, then surged by 38.98% to $2.3 million in 2025.
  • Its Finished Goods stands at $2.3 million for Q3 2025, versus $2.4 million for Q2 2025 and $1.9 million for Q1 2025.